Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition | Zendy

Slobodan Јаnkovic | Zendy; Marina Kostić | Zendy; Marija Radosavljevic | Zendy; Danka Tešić | Zendy; Natasa Stefanovic-Stoimenov | Zendy; Ivan Stevanovic | Zendy; Sladjana Rakovic | Zendy; Jelena Aleksić | Zendy; Marko Folić | Zendy; Aleksandra Aleksić | Zendy; Ivana Mihajlović | Zendy; Nenad Biorac | Zendy; Jelena Borlja | Zendy; Radosava Vuckovic | Zendy

Open Access

Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition

Author(s) -

Slobodan Јаnkovic,

Marina Kostić,

Marija Radosavljevic,

Danka Tešić,

Natasa Stefanovic-Stoimenov,

Ivan Stevanovic,

Sladjana Rakovic,

Jelena Aleksić,

Marko Folić,

Aleksandra Aleksić,

Ivana Mihajlović,

Nenad Biorac,

Jelena Borlja,

Radosava Vuckovic

Publication year - 2009

Publication title -

vojnosanitetski pregled

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.123

H-Index - 19

eISSN - 2406-0720

pISSN - 0042-8450

DOI - 10.2298/vsp0907556j

Subject(s) - medicine , glatiramer acetate , cost effectiveness , multiple sclerosis , adverse effect , socioeconomic status , demography , environmental health , immunology , population , risk analysis (engineering) , sociology

A cost-effectiveness analyses of immunomodulatory treatments for relapsing-remitting multiple sclerosis (RRMS) in developed countries have shown that any benefit from these drugs is achieved at very high cost. The aim of our study was to compare the cost-effectiveness of five treatment strategies in patients diagnosed with RRMS (symptom management alone and in combination with subcutaneous glatiramer acetate, intramuscular interferon beta-1a, subcutaneous interferon beta-1a, or intramuscular interferon [beta-1b) in a Balkan country in socio-economic transition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research